Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.

TCZ remains a valuable GC-sparing option in the oldest GCA patients with an interesting risk-benefit ratio. Mild-to-moderate adverse events were observed in one-third of patients.